Topotecan-pazopanib combination therapy for aggressive pediatric solid tumors

Posted in the Pediatric Cancer Forum


Madison, WI

#1 Jul 27, 2011
A recent study reported in the journal Clinical Cancer Research, metronomic administration of Topotecan and pazopanib showed a statistically significant antitumor activity compared to respective single agents in pediatric tumor mouse models and represent a valid option as a maintenance therapy in aggressive pediatric solid tumors. In vitro, Topotecan caused a dose-dependent decrease in viabilities of all cell lines, while pazopanib did not. In vivo, combination of Topotecan + Pazopanib (TP+PZ) demonstrated significant anti-tumor activity and significant enhancement in survival compared to the respective single agents in all models. Pharmacokinetic studies of both drugs did not reveal any drug-drug interaction. News link:

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Pediatric Cancer Discussions

Title Updated Last By Comments
Lemonade funrdaiser at UC Santa Cruz to support... (Mar '14) Mar '14 jefry helms 5
Pediatric Cancer Foundation of the Lehigh Valle... (Dec '13) Dec '13 PFfff 1
New Autism Registry Hopes to Boost Research Par... (Mar '13) Sep '13 Conor 10
Stop & Shop brings back annual Triple Winner Game (Apr '11) Sep '13 Ernesto 2
Terramed Alliance News Hope Street Kids joins C... (Oct '09) Sep '13 Weston 8
Parents work for Childhood Cancer lic. plate (Jun '09) Sep '13 Lincoln 3
Vallejo boy holds lemonade stand to raise money... (Jun '13) Jun '13 Lamont Hightower 1
More from around the web